DEA Telemedicine Prescribing Rules 2026: What They Mean for Your Practice

Every December for the past few years, telemedicine prescribers have braced for a deadline that keeps getting pushed back. Right on schedule, the DEA and HHS announced on December 31, 2025 a fourth temporary extension of the pandemic-era telemedicine prescribing flexibilities, carrying them through December 31, 2026. For providers who built their practice around virtual care, this is good news. It is also a reminder that the rules governing controlled substance prescribing by telehealth are still temporary, still evolving, and still worth understanding in detail rather than assuming they will simply renew forever.

The rule these extensions keep overriding

The underlying law here is the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. Ryan Haight requires a prescriber to conduct at least one in-person medical evaluation of a patient before prescribing a controlled substance, with narrow exceptions. The law was written to stop rogue online pharmacies from issuing prescriptions with no real clinical relationship behind them, and for most of the past decade and a half it functioned as a hard stop for fully virtual practices that wanted to prescribe anything on Schedule II through V.

That changed in March 2020, when the COVID-19 public health emergency triggered a telemedicine exception that let DEA-registered practitioners prescribe controlled substances via real-time audio-video visits without a prior in-person exam. The public health emergency ended in 2023, but DEA and HHS have extended the exception four times since, most recently through the end of 2026. Each extension has kept the substance of the original waiver essentially intact.

What the current extension actually allows

Under the extension in place now, a DEA-registered practitioner can prescribe Schedule II through V controlled medications through an audio-video telemedicine encounter without ever having conducted an in-person evaluation, as long as the prescription otherwise complies with DEA guidance and applicable state law. For Schedule III through V narcotic medications approved for opioid use disorder treatment, an audio-only encounter is sufficient. Everything else defaults to the audio-video standard, meaning a phone call alone will not satisfy the requirement for most controlled substance categories.

None of this suspends the rest of a provider’s obligations. Prescription drug monitoring program checks, proper documentation of the clinical encounter, and compliance with the patient’s state prescribing laws all still apply. The extension removes the in-person exam requirement. It does not remove everything else that makes a controlled substance prescription defensible if it is ever questioned.

The permanent framework still taking shape

DEA has made clear it does not intend to keep issuing temporary extensions indefinitely. In January 2025 the agency published a proposed rule establishing a permanent Special Registration for Telemedicine framework, and it has continued refining that proposal since. As currently structured, it would create three registration types: a Telemedicine Prescribing Registration for Schedule III through V, an Advanced Telemedicine Prescribing Registration for specialized practitioners handling Schedule II through V, and a Telemedicine Platform Registration for the online platforms that facilitate these prescriptions. The proposed rule also outlines a lower-cost State Telemedicine Registration option for practitioners who need authority in states beyond their primary one.

None of this is finalized, and the exact requirements could still shift before a final rule is published. But the direction is clear enough that practices building a telemedicine model around controlled substance prescribing should assume some version of a special registration system is coming, rather than assuming the current temporary extension is a permanent state of affairs.

The part practices often overlook

Here is where a lot of telemedicine providers get tripped up, extension or no extension. DEA registration has always been tied to a physical location, and a practitioner generally needs a registration in each state where a patient is located at the time of prescribing. That means a psychiatrist based in Ohio who wants to treat patients in Arizona needs an Arizona DEA registration, which in turn requires a physical address in Arizona. A P.O. box will not satisfy this requirement. DEA has been explicit that the address needs to be a real location where the registrant could plausibly be reached, even if the practitioner never actually sees patients in person there.

For a solo practitioner or small group expanding into a new state, standing up an actual office just to satisfy a registration requirement is a significant and often unnecessary expense. This is exactly the gap that a qualified medical coworking address is built to close: a real, verifiable Arizona location that supports DEA registration, Medicare enrollment, and state licensing, without the overhead of a full lease.

If your practice is expanding into Arizona and needs a compliant physical address to support DEA registration or other regulatory filings, Viva MedSuites can help. We provide a qualified medical address and flexible office access for telemedicine providers navigating exactly this kind of requirement, with memberships starting at $199 a month. Learn more at vivamedsuites.com/telemedicine-az-address/ or call 480-616-2400.